Table 2 Estimated characteristics of the sites
From: The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease
Site | Country | Median EIR derived from MAP PfPR2–10 | Median EIR adjusted for trial prevalence and incidence in the control | DHS estimate of access to effective treatment | Estimated access to effective treatment in trial |
|---|---|---|---|---|---|
Kilifi | Kenya | 1.1 | 0.15 | 45.0 | 53.9 |
Korogwe | Tanzania | 2.0 | 0.12 | 49.2 | 35.3 |
Manhica | Mozambique | 2.4 | 0.15 | 35.8 | 46.7 |
Lambarene | Gabon | 4.3 | 0.18 | 16.1 | 60.8 |
Bagamoyo | Tanzania | 2.9 | 0.23 | 55.4 | 54.1 |
Lilongwe | Malawi | 6.3 | 0.44 | 43.3 | 52.6 |
Agogo | Ghana | 6.3 | 2.1 | 42.5 | 63.5 |
Kombewa | Kenya | 5.2 | 8.7 | 48.8 | 59.3 |
Kintampo | Ghana | 19.5 | 13.5 | 40.5 | 53.9 |
Nanoro | Burkina Faso | 89.2 | 75.6 | 37.4 | 39.4 |
Siaya | Kenya | 34.5 | 86.6 | 48.8 | 50.9 |